PURPOSE AND METHODS: Central venous catheter (CVC)-related thrombosis and infections are frequently occurring complications in patients with hematological malignancies. At present, heparin is most often used as a locking solution. Trisodium citrate (TSC) had been shown to be a very effective antimicrobial catheter locking in hemodialysis patients. We performed a prospective randomized phase III multicenter trial to determine the efficacy of TSC as a locking solution compared to heparin in preventing CVC-related thrombosis and infections in patients with hematological malignancies. RESULTS:Thirty-four episodes of CVC-related bloodstream infections (CVC-BSI) occurred in the 108 patients who were randomized to locking withheparin compared with 35 episodes in the 99 patients who were randomized to locking with TSC (P = 0.654). We did find seven times more CVC-BSI with gram-negative rods in CVCs locked with heparin (P = 0.041). The cumulative incidence of symptomatic thrombosis was 10% in the heparin group and 5% in the TSC group (hazard ratio 0.525; 95% confidence interval 0.182-1.512). CONCLUSION: This study shows that locking with TSC in patients with hematological malignancies significantly reduced the incidence of CVC-BSI with gram-negative rods. However, the incidence of CVC-BSI with coagulase-negative staphylococcus or CVC-related thrombosis was not reduced by TSC locking.
RCT Entities:
PURPOSE AND METHODS: Central venous catheter (CVC)-related thrombosis and infections are frequently occurring complications in patients with hematological malignancies. At present, heparin is most often used as a locking solution. Trisodium citrate (TSC) had been shown to be a very effective antimicrobial catheter locking in hemodialysis patients. We performed a prospective randomized phase III multicenter trial to determine the efficacy of TSC as a locking solution compared to heparin in preventing CVC-related thrombosis and infections in patients with hematological malignancies. RESULTS: Thirty-four episodes of CVC-related bloodstream infections (CVC-BSI) occurred in the 108 patients who were randomized to locking with heparin compared with 35 episodes in the 99 patients who were randomized to locking with TSC (P = 0.654). We did find seven times more CVC-BSI with gram-negative rods in CVCs locked with heparin (P = 0.041). The cumulative incidence of symptomatic thrombosis was 10% in the heparin group and 5% in the TSC group (hazard ratio 0.525; 95% confidence interval 0.182-1.512). CONCLUSION: This study shows that locking with TSC in patients with hematological malignancies significantly reduced the incidence of CVC-BSI with gram-negative rods. However, the incidence of CVC-BSI with coagulase-negative staphylococcus or CVC-related thrombosis was not reduced by TSC locking.
Authors: Marcel C Weijmer; Yvette J Debets-Ossenkopp; Francien J Van De Vondervoort; Piet M ter Wee Journal: Nephrol Dial Transplant Date: 2002-12 Impact factor: 5.992
Authors: Florian Lordick; Markus Hentrich; Thomas Decker; Michael Hennig; Hans Pohlmann; Reiner Hartenstein; Christian Peschel Journal: Br J Haematol Date: 2003-03 Impact factor: 6.998
Authors: Lennert Slobbe; Jeanette K Doorduijn; Pieternella J Lugtenburg; Abdelilah El Barzouhi; Eric Boersma; Willem B van Leeuwen; Bart J A Rijnders Journal: PLoS One Date: 2010-05-26 Impact factor: 3.240
Authors: Lei Zhong; Hai-Li Wang; Bo Xu; Yao Yuan; Xin Wang; Ying-Ying Zhang; Li Ji; Zi-Mu Pan; Zhan-Sheng Hu Journal: Crit Care Date: 2017-01-08 Impact factor: 9.097